SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001725160-24-000089
Filing Date
2024-04-11
Accepted
2024-04-11 07:02:13
Documents
3
Period of Report
2024-04-05

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1712833324.html 3  
1 FORM 3 wk-form3_1712833324.xml 3 10134
2 EX-24 vvultaggiosection16filin.htm EX-24 3914
3 vvultaggiosection16filin001.jpg GRAPHIC 243100
  Complete submission text file 0001725160-24-000089.txt   350621
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Vultaggio Vincent (Reporting) CIK: 0002018766 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39263 | Film No.: 24837109